Abstract
Angiogenesis inhibitors have a major role in the treatment of varying cancers today. While originally thought to be independent of resistance, increasing data suggests varying mechanisms that bring about drug resistance, either intrinsically or through adaptation. The role of vascular endothelial growth factor single nucleotide polymorphisms (VEGF SNPs) in terms of therapeutic response and toxicity has increasingly been recognized, as well as its potential for contributing to drug resistance. This review will focus on theories, preclinical models, and clinical trials that help elucidate the mechanisms of resistance and clinical response to angiogenesis inhibitors.
Keywords: Angiogenesis, angiogenesis inhibitors, polymorphisms, drug resistance, toxicity
Anti-Cancer Agents in Medicinal Chemistry
Title: Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Volume: 10 Issue: 8
Author(s): Jahan Tavakoli and Jeanny B. Aragon-Ching
Affiliation:
Keywords: Angiogenesis, angiogenesis inhibitors, polymorphisms, drug resistance, toxicity
Abstract: Angiogenesis inhibitors have a major role in the treatment of varying cancers today. While originally thought to be independent of resistance, increasing data suggests varying mechanisms that bring about drug resistance, either intrinsically or through adaptation. The role of vascular endothelial growth factor single nucleotide polymorphisms (VEGF SNPs) in terms of therapeutic response and toxicity has increasingly been recognized, as well as its potential for contributing to drug resistance. This review will focus on theories, preclinical models, and clinical trials that help elucidate the mechanisms of resistance and clinical response to angiogenesis inhibitors.
Export Options
About this article
Cite this article as:
Tavakoli Jahan and B. Aragon-Ching Jeanny, Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/187152010794473948
DOI https://dx.doi.org/10.2174/187152010794473948 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology PET/CT Dose Planning for Volumetric Modulated arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer Patients
Current Radiopharmaceuticals Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design Anticancer Effects of Cinnamaldehyde Through Inhibition of ErbB2/HSF1/LDHA Pathway in 5637 Cell Line of Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry